Malaria [strain 7G8] vaccine is under clinical development by Sanaria and currently in Phase II for Malaria. According to GlobalData, Phase II drugs for Malaria have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Malaria [strain 7G8] vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Malaria [strain 7G8] vaccine overview

Vaccine candidate is under development for the prevention of malaria. It is administered through intravenous route by direct venous inoculation (DVI). The therapeutic candidate constitutes radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ), derived from a clone of a Brazilian isolate, 7G8.

Sanaria overview

Sanaria is a biotechnology company that offers vaccines for the treatment of malaria caused by the pathogen Plasmodium falciparum. The company develops radiation-attenuated sporozoites as a human vaccine. It offers products such as plasmodium falciparum sporozoite reagents, PfSPZ challenge mosquitoes, plasmodium reagents, plasmodium reagent slides, anopheles reagents and recombinant proteins and antibodies. Sanaria also develops and commercializes attenuated whole parasite malaria vaccines. The company provides products such as recombinant proteins and antibodies and custom services. Sanaria is headquartered in Rockville, Maryland, the US.

For a complete picture of Malaria [strain 7G8] vaccine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.